As mice developing NSCLC induced by activation of mutant alleles of Kras and Trp53 recapitulate the therapeutic responses observed in the clinic [25], we chose to evaluate the anti-neoplastic activity of the pan-NOS inhibitor L-NAME in this genetically engineered mouse model of Kras mutation-positive NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.